Home
Services
About Us
Contact Us

Spinifex Pharmaceuticals, a pain drug development company, raises $45MM in Series C financing.

April 12, 2014/in News /by Competitive

Continue reading →

Tags: angiotensin II type 2 receptor antagonist, Brandon Capital Partners, Canaan Partners, chronic pain, GBS Venture Partners, Novo A/S, Phase 2, Series C, UniQuest, Uniseed

Share this entry

You might also like

Truveris raises $12.75MM in a Series C financing round led by Canaan Partners to further develop its…

Search

Tags

1st Pitch Life Sciences angiotensin II type 2 receptor antagonist autoimmune disease Best in Show Big Data biotechnology BoxGroup Brandon Capital Partners Canaan Partners Catalyst Health Ventures chronic pain Connecticut Innovations electronic medical records employee health benefits eye-tracking technology First Round flu GBS Venture Partners Google Ventures Harris & Harris Group infectious disease inflammation Lerer Ventures Mid-Atlantic Bio Angels New Atlantic Ventures New Leaf Venture Partners non-dilutive financing non-surgical device Novo A/S oncology Phase 2 prescription benefits protein degradation SaaS Series A Series B Series C Serious Change stress urinary incontinence Tribeca Venture Partners UniQuest Uniseed vaccine Vaizra Investments ventilator-associated pneumonia

Archive of news

February 2015
January 2015
December 2014
November 2014
October 2014
July 2014
June 2014
May 2014
April 2014
March 2014
January 2014
December 2013
September 2013

© 2015 All rights reserved - Drevo Analytics, LLC

Accessibility
Credits
Privacy Policy
Terms of Use

Connecticut-based Contine Corporation takes the win for Mid Atlantic Bio Angels’...

Flatiron Health secures $130MM in Series B round led by Google Ventures.

Scroll to top